Merck & Co., Inc. logo

Merck & Co., Inc. (MRK)

Market Closed
9 Jun, 20:00
$
79. 33
+0.36
+0.46%
$
196.54B Market Cap
58.39 P/E Ratio
3.08% Div Yield
10,744,739 Volume
1.46 Eps
$ 78.97
Previous Close
Day Range
78.67 80.41
Year Range
73.31 134.63
Earnings results expected in 49 days
Want to track MRK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Merck's cholesterol drug meets main goal in late-stage studies

Merck's cholesterol drug meets main goal in late-stage studies

Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies.

Reuters | 13 hours ago
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.

Zacks | 1 week ago
Merck Stock's Ticking Keytruda Time Bomb

Merck Stock's Ticking Keytruda Time Bomb

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.

Forbes | 1 week ago
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.

Seekingalpha | 1 week ago
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 week ago
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, patritumab deruxtecan (HER3-DXd) based on the HERTHENA-Lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies has.

Businesswire | 1 week ago
Merck Proves Why It's Still A Top Pharma Pick

Merck Proves Why It's Still A Top Pharma Pick

Despite a catastrophic drop in sales of the Gardasil franchise, mainly due to weak demand from China, Merck once again beat consensus EPS and revenue estimates. So, the key contributors whose performance pleasantly surprised me in Q1 2025, and thanks to which Merck's operating income margin remains above 40%, are Vaxneuvance, Winrevair, and Welireg. From its oncology franchise, I highlight Welireg as a 'gem,' whose sales amounted to $137 million in the first three months of 2025, an increase of 61.2% year-on-year.

Seekingalpha | 1 week ago
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?

MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?

Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.

Zacks | 2 weeks ago
Should You Buy MRK Stock At $80?

Should You Buy MRK Stock At $80?

Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term growth prospects of its blockbuster drugs, Keytruda and Gardasil.

Forbes | 2 weeks ago
Merck: Defensive Yield Meets Long-Term Optionality

Merck: Defensive Yield Meets Long-Term Optionality

The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology, and vaccines through acquisitions and R&D, offering long-term optionality beyond Keytruda. Gardasil's China-driven slump has limited downside left, with stable ex-China growth and male-use approval offering medium-term recovery potential.

Seekingalpha | 2 weeks ago
Merck: Undervalued In Light Of Key Risks

Merck: Undervalued In Light Of Key Risks

Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially Keytruda—drives strong segment performance, offsetting declines in virology and diabetes products. Management is aggressively investing in R&D and manufacturing expansion, with a robust drug pipeline and significant capital commitments to future growth.

Seekingalpha | 2 weeks ago
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

Zacks | 2 weeks ago
Loading...
Load More